Abstract:e24276 Background: Hepatocellular carcinoma (HCC), the most common hepatic malignancy, is the second leading cause of cancer-related death worldwide. China accounts for more than 50% of new HCC cases and deaths in the world. The genomic profiles of HCC in Chinese patients had not been thoroughly elucidated to facilitate diagnosis and treatment. Methods: FFPE tumor and matched blood samples of 181 Chinese HCC patients, including 152 males (median age of 54) and 29 females (median age of 52), were collected for next-generation sequencing-based 450 genes panel assay. Genomic alterations (including single base substitutions, short and long insertions/deletions, copy number variations, and gene rearrangement in selected genes) and tumor mutational burden were assessed. In addition, the expression of tumor cell PDL1 was also evaluated by FDA-cleared DAKO 22c3 antibody. Results: The most frequently mutated genes in 181 Chinese HCC were TP53 (59.7%), TERT (34.3%), CTNNB1 (21.5%), AXIN1 (12.2%), RB1 (11.0%), STK24 (11.0%), ARID1A (9.9%), CCND1 (7.7%), TSC2 (6.6%) and FGF19 (6.6%). The mutation rates of TERT (p = 0.027) and RB1 (p = 0.016) were significantly higher in patients (pts) with TMB greater than the cohort medium of 7.2 muts/Mb. In addition, loss of function mutation of PBRM1 was found in 2.8% of the pts. About 7% of the patients had TMB value higher than 20 muts/Mb, compared to 1-2% in Western HCC pts, and 31% higher than 10 muts/Mb. Seventy-four patients (median age 54 years; median TMB 6.8 muts/Mb) had tumorous PDL1 expressions assessed by IHC assay. Thirty-six percent of patients were positive of PDL1 (tumor portion score TPS greater than 1%). Only three pts possessed both high TMB and high PDL1 expression (TPS > 50). No correlation was observed between the expression of PDL1 and TMB (r = 0.1). Conclusions: This is the first genomic profiling study of Chinese HCC pts along with TMB and PDL1 expression results. With less actionable gene alterations but more often high TMB and PDL1 expression than their Western counterparts, Chinese HCC pts could potentially benefit more from immune check point inhibitor-based therapies. However, no correlation was observed between the expressions of PDL1 and TMB values.

META-ANALYSIS OF RELATIONSHIP BETWEEN TUMOR SUPPRESSOR GENE P16,RUNX 3 GENE METHYLATION AND SUSCEPTIBILITY OF HEPATIC CARCINOMAIN IN THE ASIA-PACIFIC REGION

Effects Of Methylation Of P16 Gene, Polymorphism Of Gstm1 Gene And Environmental Factors On Susceptibility To Lung Cancer

Association of Low P16ink4a and P15ink4b Mrnas Expression with Their Cpg Islands Methylation with Human Hepatocellular Carcinogenesis

The effects of p16 gene methylation on the risk of non-small cell lung cancer

Association of Abnormal Methylation of CpG Islands in Promoter Domains of Multiple Tumor Suppressor Genes with Non-Small Cell Lung Cancer

STUDY ON THE METHYLATION OF P16 GENE AND GENETIC POLYMORPHISM OF GSTM1 GENE RELATED WITH SUSCEPTIBILITY TO NON-SMALL CELL LUNG CANCER

Relationship Between P21,p53 Expression and Single Nucleotide Polymorphism with Hepatocellular Carcinoma

Characterization of Genomic Alterations, Tumor Mutational Burden and PDL1 Expression in 181 Chinese Hepatocellular Carcinomas.

P16 Methylation Was Associated with the Development, Age, Hepatic Viruses Infection of Hepatocellular Carcinoma, and P16 Expression Had a Poor Survival

Contribution of DNA methylation to the risk of hepatitis C virus-associated hepatocellular carcinoma: A meta-analysis

Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis

p16 Methylation was associated with the development, age, hepatic viruses infection of hepatocellular carcinoma, and p16 expression had a poor survival: A systematic meta-analysis (PRISMA)

The Prognostic Value Of P16 Hypermethylation In Cancer: A Meta-Analysis

RETRACTED ARTICLE: Role of P16 Gene Promoter Methylation in Gastric Carcinogenesis: a Meta-Analysis

Association between P16INK4a Promoter Methylation and HNSCC: A Meta-Analysis of 21 Published Studies

Correlation Between Suppressor Genes Promoter Hypermethylation and Chemosensitivity of Gastric Cancer

P16 Promoter Hypermethylation is Associated with Increased Breast Cancer Risk

Meta-Analysis Of Dna Methylation Biomarkers In Hepatocellular Carcinoma

Aberrant Methylation Status of SPG20 Promoter in Hepatocellular Carcinoma: A Potential Tumor Metastasis Biomarker.

The Association Between Methylation Patterns of DNAH17 and Clinicopathological Factors in Hepatocellular Carcinoma

Methylation Patterns of RASA3 Associated with Clinicopathological Factors in Hepatocellular Carcinoma.